A new severe respiratory illness caused by a newly identified virus is discovered. Which of the following properties of a killed vaccine relative to a live vaccine is the most appropriate rationale for developing a killed vaccine for this illness?

A) Greater immunogenicity
B) Longer duration of protection
C) Safer for immunocompromised individuals
D) Faster onset of immunity